<DOC>
	<DOCNO>NCT02703181</DOCNO>
	<brief_summary>The current study design assess safety , tolerability pharmacokinetics ( PK ) additional repeat dos epelsiban healthy female , first dose experience repeat dose high dos woman compound . This study 14 day , randomize , placebo-controlled , double blind ( sponsor unblind ) , repeat dose , ascend cohort , dose escalation study healthy , female volunteer . Upon successful completion Screening period , subject enrol study . The study compose three period : Screening , Treatment Follow-up . A subject 's total time involve study approximately six week . Cohorts conduct sequentially . Each subject enrol one cohort . Ten subject enrol cohort randomize epelsiban ( n=8 ) placebo ( n=2 ) .</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Pharmacokinetics , Safety , Tolerability Epelsiban Administered Repeat Doses Healthy Women Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>Female 18 55 year age inclusive , time consent Healthy determine investigator medically qualify designee base medical evaluation include medical history , review medication previously use , physical examination , laboratory test electrocardiogram ( ECG ) . Body mass index ( BMI ) within range 18 35 kilogram per square meter ( kg/m^2 ) ( inclusive ) Not pregnant ( confirmed negative serum human chorionic gonadotropin [ hCG ] test ) , lactate , least one follow condition applies : Nonreproductive potential define : Premenopausal female , postmenopausal , woman reproductive potential agree follow one option list GlaxoSmithKline ( GSK ) Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential . History clinically significant abnormal transvaginal ultrasound Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT interval ( QTc ) &gt; 450 millisecond ( msec ) History regular alcohol consumption within three month dose Day 1 define : average weekly intake &gt; 7 drink . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within three month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug know inhibit induce Cytochrome P450 3A4 [ P450 CYP3A4 ] ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within three month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within three month The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Repeat Dosing</keyword>
	<keyword>Epelsiban</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Women Volunteers</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Oxytocin</keyword>
</DOC>